Protalix BioTherapeutics, Inc. Common Stock (PLX) is a publicly traded Healthcare sector company. As of August 5, 2026, PLX trades at $2.37 with a market cap of $186.93M and a P/E ratio of 11.82. PLX moved +2.16% today. Year to date, PLX is +31.67%; over the trailing twelve months it is +58.00%. Its 52-week range spans $1.32 to $3.19. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces PLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
1 analysts cover PLX: 0 strong buy, 1 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $12.00.
| Metric | Value |
|---|---|
| Price | $2.37 |
| Market Cap | $186.93M |
| P/E Ratio | 11.82 |
| EPS | $0.20 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.19 |
| 52-Week Low | $1.32 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $76.38M |
| Net Income | $15.33M |
| Gross Margin | 69.97% |
1 analysts cover PLX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.